《新股消息》外电指京东健康招股价62.8至70.58元筹最多35亿美元 成亚洲最大医疗健康IPO
据《彭博通讯社》报道,京东健康在港上市料筹最多35亿美元,并将成亚洲最大医疗健康IPO。报道指京东健康计划发售3.82亿股,招股价介乎62.8至70.58元,而估值则介乎253至286亿美元,而是次上市联席保荐人为美银、海通国际及瑞银,料将在12月1日定价,并在12月8日上市。
据悉京东健康已锁定6个基石投资者,包括是新加坡政府投资公司GIC、高瓴资本及贝莱德,并同意认购最多总值13.5亿美元的股份。京东健康是内地最大的线上医疗健康平台及线上零售药房,公司今年上半年收入达88亿元人民币。(el/k) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.